Introduction
RAS genes, such as KRAS2, frequently undergo activating mutations in several human and other animal cancers, including lung adenocarcinomas (ADCAs) (Ellis and Clark, 2000; Mascaux et al., 2005) . KRAS2 mutations play a causative role in lung cancer development, since transgenic mice carrying an activated KRAS2 gene develop lung cancer early in life and at high frequency (Johnson et al., 2001) . In human lung cancer, the presence of KRAS2 mutations is associated with poor prognosis (De Gregorio et al., 1998; Huncharek et al., 1999) .
Ras proteins are pivotal in many signal transduction pathways that transfer information from the extracellular environment to the internal cellular compartments (Malumbres and Barbacid, 2003) . Thus, mutationinduced deregulation of Ras activity may result in important alterations of cell growth control and differentiation.
In mammals, the RAS signaling pathway is mediated by numerous effectors, including proteins with a RASassociated (RalGDS/AF-6) (RA) domain (Malumbres and Barbacid, 2003; Wohlgemuth et al., 2005) . Interestingly, the genes C11ORF13 at 25.9 kb from the HRAS1 gene on Chromosome 11 and RASSF8 (Ras association (RalGDS/AF-6) domain family 8) at 70.8 kb from the KRAS2 gene on Chromosome 12 (http://www.ensembl. org/Homo_sapiens/), contain a RAS (RalGDS/AF-6) domain mapping near the two RAS genes. The presence of such domains close to RAS genes suggests the conservation of functional genomic fragments (Wall and Pritchard, 2003) and a possible involvement of these proteins in the RAS signaling pathway, although the presence of the RA domain does not necessarily signify RAS binding affinity of a protein Wohlgemuth et al., 2005) .
In the light of the important role of RAS genes in cancer, it seems likely that proteins involved in the RAS signaling pathway are also involved in modulation of cancer development. Indeed, several proteins containing an RA domain are inactivated in human cancers and act as tumor suppressor genes (Dammann et al., 2000; Hesson et al., 2003) .
Here, we analysed mRNA expression of the RASSF8 gene in human normal and tumor lung tissue, and studied functional activities of the full-length transcript through overexpression in A549 or NCI-H520 lung carcinoma cells.
Results

RASSF8 gene is downregulated in lung ADCAs
Screening of the full-length human lung cDNA library revealed a RASSF8 clone (B4-E11) of 5472 bp (Acc. #AY665468) encoding a 419-amino acids putative protein (Acc. #AAV54603), which showed 99% identity with the annotated protein BAC98838. Since analysis of EST clones reported in public databases suggested the presence of several 5 0 -UTR variants for the RASSF8 transcript, we used primers mapping in common regions to analyse 5 0 -UTR expression in human lung mRNAs. Four 5 0 -UTR variants originating from alternative splicing of exons 1-3 were identified, whose relative abundance was similar in normal and tumor samples (Figure 1 ), suggesting no tumor-specific expression of these variants. However, kRT-PCR analysis of RASSF8 mRNA levels carried out in paired normal or ADCA tissue of 20 lung ADCA patients revealed a clear expression of transcript AY665468 in normal lungs, a B6.7-fold decreased abundance in lung ADCA (Figure 2 , Po0.0001), and >50-fold decreased abundance in both A549 and NCI-H520 cancer cells (not shown).
RASSF8-transfected clones show reduced anchorage-independent growth A549 cells stably transfected with RASSF8 were screened for RASSF8 protein expression. A single clone and two bulk transfectants (containing approximately 100-200 individual clones) stably expressing RASSF8 protein ( Figure 3a and not shown) were assayed for clonogenicity and anchorage-independent growth. Clonogenic assays of A549 transfectants carried out in complete serum (10%) or in reduced serum (0.5%) revealed similar colony numbers in vector-or RASSF8-transfected cells (not shown). Comparison of growth curves of A549 cells transfected with control vector and of RASSF8 stable transfected cells showed no apparent differences (not shown). Anchorage-independence assays in soft agar revealed similar-sized large colonies formed from nontransfected or vector-transfected A549 cells, whereas the stable RASSF8 transfectant and the two independent RASSF8 bulk transfectants formed smaller, similarly sized colonies ( Figure 3c ). Thus, the two control groups and the three RASSF8-transfected clones were grouped together, respectively, and used for comparison. Mean colony area was B1.7-fold higher in control than in RASSF8-transfected A549 cells (Figure 3b , Po0.001), and the number of colonies >0.12 mm in diameter was 2.6-fold higher in control than in RASSF8-transfected A549 cells (not shown).
Transfection of RASSF8 in NCI-H520 cells produced a B12-fold reduction in clonogenic activity: the number of colonies with diameter >0.5 mm was 22.273.1 (mean7s.e.) and 280.676.8 in transfected and control cells, respectively (Po0.0001; Figure 4 ).
Discussion
RASSF8 protein is evolutionarily very well-conserved with 66% identity and 83% positives between the Danio rerio homologous NP_956657 protein sequence and the human AAV54603. The RASSF8 cDNA that we have isolated (AY665468) consists of five exons and it covers 113.8 kb. RASSF8 has been implicated in a complex type of synpolydactyly by the reciprocal chromosomal translocation t(12;22)(p11.2;q13.3), which involves genes RASSF8 and FBLN1 (Debeer et al., 2002) .
The biochemical activity of the RASSF8 protein remains unclear, although the presence of an RA domain in the N-terminal region suggests involvement of the protein in the RAS signaling pathway. Alterations in such a pathway are involved in a variety of malignancies, including lung cancer, and affect both tumor initiation and tumor progression (Campbell and Der, 2004) . In silico prediction of the RAS binding affinity using the computer algorithm FoldX (http:// foldx.embl.de) (Guerois et al., 2002; Wohlgemuth et al., 2005) showed that the predicted complex stabilities are in the twighlight zone (based on the À7 kcal/mol threshold for binding/nonbinding domains) , leaving it uncertain whether the RA domain of RASSF8 indeed binds to Ras proteins. Nevertheless, sequence alignment of the RA domain family shows that RASSF8 contains the positively charged amino-acid residues (Lys, Arg, and Arg) in b1, b1 and the first helix, respectively, important for binding to Ras proteins Wohlgemuth et al., 2005) . Since the prediction method is heavily based on the use of different template structures in order to account for small structural changes in the interface, it is possible that the position of secondary structure elements differs slightly, so that small details in the interface cannot be modelled correctly . The RASSF8 gene revealed a complex pattern of expression of its 5 0 -UTR mRNA isoforms in normal lung and in lung ADCAs, with no apparent differences between normal and tumor tissue in the relative abundance of these isoforms (Figure 1 ). However, quantitative real-time RT-PCR showed a B6.7-fold decrease in RASSF8 transcript abundance in lung ADCA as compared to normal lung tissue (Figure 2 ), raising the possibility that this gene plays a role in the negative control of tumor development. A549 cells, derived from a human lung cancer, expressed the RASSF8 protein when transfected with a recombinant mammalian expression vector containing the RASSF8 protein (Figure 3 ). Clonogenic assay of RASSF8-transfected and control A549 cells revealed no significant effect of RASSF8 protein overexpression on cancer cell viability, since colony numbers were similar. However, anchorage-independent growth in soft agar, which is correlated with tumor progression and metastasis formation (Nikiforov et al., 1996; Clezardin, 1998; Jiang et al., 2001; Malaney and Daly, 2001; Nakanishi et al., 2002) , was significantly reduced in the RASSF8-transfected A549 cells (Figure 3b and c) . Moreover, RASSF8 transfection inhibited clonogenic activity in NCI-H520 cancer cell line. Thus, the RASSF8 gene may represent a novel molecular target involved in lung cancer development. 
Materials and methods
Human tissue samples
Lung adenocarcinoma (ADCA) surgical specimens and the corresponding normal lung tissue were obtained from pathologically documented patients enrolled at Istituto Nazionale Tumori, Milan, Italy. Clinical data were available with informed consent and approval of the Institute Ethics Committee. Total RNA was extracted from normal and tumor lung tissue with RNeasy Midi kit (Qiagen, Valencia, CA, USA).
cDNA cloning RASSF8 transcripts were cloned by screening a full-length human lung cDNA library (OriGene Technologies, Rockville, MD, USA) according to the manufacturer's instructions using PCR primers designed for the coding region (5 0 -gggaacc gaaaaggaaatca-3 0 , 5 0 -gcaccttttgcttaaactc-3 0 ). PCR was carried out in 1X buffer II (10 mM Tris-HCl pH 8.3, 50 mM KCl) (Applied Biosystems, Foster City, CA, USA) and 1.5 mM MgCl 2 , 200 mM dNTPs, 7 pmoles primers, and 0.6 U AmpliTaq Gold (Applied Biosystems).
The 5 0 -ends of the RASSF8 gene were determined by RT-PCR of a cDNA sample prepared from human normal lung tissue, using the primers 5 0 -ctgcgggggcggcgcagtt-3 0 (exon 1) and 5 0 -ctgaactccatccacccatact-3 0 (exon 3), and subcloned into a plasmid vector. Nucleotide sequences of the isolated plasmid clones were obtained using an ABI PRISM 377 automatic sequencer or a 3100 Genetic Analyser (Applied Biosystems).
mRNA expression and quantitative real-time RT-PCR analysis cDNAs were prepared by reverse-transcription using oligo(dT) primers and ThermoScript RT (Invitrogen, Carlsbad, CA, USA). Kinetically monitored reverse transcriptase PCR (kRT-PCR) amplification mixtures contained 0.5 ml template cDNA, 12.5 ml 2 Â QuantiTect SYBRGreen PCR Master Mix (Qiagen), and 0.3 mM intron-spanning gene-specific primers (5 0 -agcagttcatccagcagaca-3 0 ; 5 0 -gagatgaaccaggtcgcttc-3 0 ) designed using Primer3 software (http://www.broad.mit.edu/ cgi-bin/primer/primer3_www.cgi). Final volume was adjusted to 25 ml with water. The human hydroxymethylbilane synthase (HMBS) gene (GenBank Acc. No. NM_000190) served as a housekeeping control for possible differences in the amount of cDNA used (primers: 5 0 -aggatgggcaactgtacctg-3 0 ; 5 0 -gcctac caactgtgggtcat-3 0 ). Relative expression was calculated with the 2
ÀDCt method, where DC t ¼ C t (target mRNA) -C t (control gene). All real-time assays were run in duplicate on an ABI GeneAmp 5700 sequence detection system (Applied Biosystems).
mRNA expression of the 5 0 -UTR of the RASSF8 gene was determined in six pairs of human normal lung and lung adenocarcinoma tissues, using the previously indicated primers for exons 1 and 3. PCR products were run on 5% agarose gels and stained with ethidium bromide.
Transfection and in vitro assays
The RASSF8 gene coding region was amplified from the cDNA clone isolated from a full-length human lung plasmid cDNA library (OriGene Technologies) using primers 5 0 -ggtgcaccatggaacttaaa-3 0 and 5 0 -gacatatatgccttcaggatta-3 0 . PCR aliquots were subcloned in the pEF6/V5-His TOPO vector to be in-frame with the V5 epitope and polyhistidine tag. Clones were screened and sequenced using vector-specific primers.
Human cell lines A549 and NCI-H520, derived from lung carcinoma and lung squamous cell carcinoma, respectively, were transfected with 2.5 mg DNA of recombinant or control vector (pEF6/V5-His-TOPO) using SuperFect Transfection Reagent (Qiagen) with or Nupherint-neuron (Biomol). Transfected clones were selected with blasticidin 5 mg/ml (Invitrogen) for 3 (A549) or 4 (NCI-H520) weeks, methanolfixed and stained with 10% Giemsa. The clonogenic assay was carried out in selective medium containing 10% serum; additionally, A549 cells were tested in low-serum (0.5% FBS) medium.
Cell proliferation was measured using Alamar Blue (BioSource International) diluted to 10% in complete cell culture medium. Thousand cells were plated in 48-well plate and fluorescence was measured daily for 1 week using Ultra fluorometer (Tecan). Cell proliferation was measured as Alamar Blue reduction.
Protein extracts from confluent A549 control and transfected cells were mixed with 1 mg of anti-V5 monoclonal antibody (Invitrogen) and Protein-G Sepharose (Sigma) and incubated overnight at 41C. The mixture was washed, eluted, separated electrophoretically on a polyacrylamide gel, and transfrerred onto Hybond-C nitrocellulose membranes (Amersham) using the Trans-Blot Semi-Dry system (Biorad). Membranes were incubated overnight at 41C with hybridization solution containing anti-V5 antibody (1:5000 dilution). The ECL system (Amersham) was used for detection.
Anchorage-independent growth was assayed based on growth in soft agar prepared in medium containing serum and 0.5% agarose (Sigma) in 24-multi-well plates and overlayered with 3000 cells resuspended in medium containing serum and 0.33% agarose (Sigma). Cells were incubated at 371C for 4 weeks. Resulting colonies were stained overnight with the dye contained in the Cell Transformation Detection kit (Chemicon).
Data analysis
Nucleotide and protein sequences were aligned and compared using Genetics Computer Group (GCG) software, Genomatix Dialign software (http://www.genomatix.de), or BLAST software (http://www.ncbi.nlm.nih.gov/BLAST). Differences between groups in cell growth, clonogenic activity, or mRNA levels were determined using univariate analysis of variance (SPSS 10.1, SPSS Inc., Chicago, IL, USA).
